Hillsdale Investment Management Inc. Intra Cellular Therapies, Inc. Transaction History

Hillsdale Investment Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$64.76 - $79.84 $647 - $798	10 Added 12.5%	90 $6,000
Q4 2023 Feb 09, 2024	SELL	$46.37 - $73.65 $2.35 Million - $3.73 Million	-50,620 Reduced 99.84%	80 $5,000
Q3 2023 Nov 09, 2023	BUY	$52.09 - $64.1 $116,681 - $143,584	2,240 Added 4.62%	50,700 $2.64 Million
Q2 2023 Aug 11, 2023	SELL	$54.67 - $66.44 $1.98 Million - $2.4 Million	-36,140 Reduced 42.72%	48,460 $3.07 Million
Q1 2023 May 10, 2023	SELL	$43.8 - $56.99 $494,939 - $643,987	-11,300 Reduced 11.78%	84,600 $4.58 Million
Q4 2022 Feb 13, 2023	BUY	$44.07 - $54.45 $83,733 - $103,455	1,900 Added 2.02%	95,900 $5.08 Million
Q3 2022 Nov 10, 2022	BUY	$42.7 - $59.99 $3.41 Million - $4.79 Million	79,900 Added 566.67%	94,000 $4.37 Million
Q2 2022 Aug 12, 2022	BUY	$43.0 - $65.64 $606,300 - $925,524	14,100 New	14,100 $805,000

381

84M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $11.9B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.